Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8263120 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(1 year, 11 months from now) | |
US8486446 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(1 year, 11 months from now) | |
US8741948 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(1 year, 11 months from now) | |
US8529945 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(1 year, 11 months from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 16, 2023 |
Generating Antibiotic Incentives Now (GAIN) | Nov 16, 2028 |
Drugs and Companies using RIFAMYCIN SODIUM ingredient
NCE-1 date: 2027-11-17
Market Authorisation Date: 16 November, 2018
Treatment: Treatment of travelers' diarrhea caused by non-invasive strains of escherichia coli in adults
Dosage: TABLET, DELAYED RELEASE;ORAL
10
United States
3
European Union
2
China
2
Canada
2
Japan
2
Korea, Republic of
1
Italy
1
Spain
1
Austria
1
Denmark
1
RS
1
Germany
1
Poland
1
Croatia
1
Cyprus
1
Portugal
1
Mexico
1
South Africa
1
Slovenia
1
Hungary
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8802637 | THERACOSBIO | Benzylbenzene derivatives and methods of use |
Aug, 2028
(5 years from now) | |
US7838499 | THERACOSBIO | Benzylbenzene derivatives and methods of use |
Jan, 2029
(5 years from now) | |
US10981942 | THERACOSBIO | Crystalline form of benzylbenzene SGLT2 inhibitor |
Jun, 2031
(8 years from now) | |
US8987323 | THERACOSBIO | Crystalline form of benzylbenzene SGLT2 inhibitor |
May, 2032
(8 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8106021 | THERACOSBIO | Benzylbenzene derivatives and methods of use |
Aug, 2028
(5 years from now) | |
US10533032 | THERACOSBIO | Crystalline form of benzylbenzene SGLT2 inhibitor |
Jul, 2031
(8 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 20, 2028 |
Drugs and Companies using BEXAGLIFLOZIN ingredient
NCE-1 date: 2027-01-20
Market Authorisation Date: 20 January, 2023
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US11370755 | ACADIA PHARMS INC | Compositions of trofinetide |
Aug, 2040
(17 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9212204 | ACADIA PHARMS INC | Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid |
Jan, 2032
(8 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Mar 10, 2030 |
New Chemical Entity Exclusivity (NCE) | Mar 10, 2028 |
Drugs and Companies using TROFINETIDE ingredient
NCE-1 date: 2027-03-11
Market Authorisation Date: 10 March, 2023
Treatment: Treatment of rett syndrome or a symptom thereof
Dosage: SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9993461 | TRAVERE | Method for treating disorders associated with glomerular function |
Mar, 2030
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Feb 17, 2030 |
New Chemical Entity Exclusivity (NCE) | Feb 17, 2028 |
Drugs and Companies using SPARSENTAN ingredient
NCE-1 date: 2027-02-17
Market Authorisation Date: 17 February, 2023
Treatment: Treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10695323 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(13 years from now) | |
US10342780 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(13 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10464905 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(13 years from now) | |
US10918622 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jan 27, 2030 |
New Chemical Entity Exclusivity (NCE) | Jan 27, 2028 |
Drugs and Companies using PIRTOBRUTINIB ingredient
NCE-1 date: 2027-01-27
Market Authorisation Date: 27 January, 2023
Treatment: Treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after at least two lines of systemic therapy, including a btk inhibitor
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8324208 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Dec, 2028
(5 years from now) | |
US11117871 | GLAXOSMITHKLINE | Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof |
Mar, 2038
(14 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8557834 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Jun, 2027
(4 years from now) | |
US8815884 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Jun, 2027
(4 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 1, 2028 |
Drugs and Companies using DAPRODUSTAT ingredient
NCE-1 date: 2027-02-01
Market Authorisation Date: 01 February, 2023
Treatment: Treatment of anemia due to chronic kidney disease; A method of treating anemia
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8653092 | PHARMING | Tetrahydro-pyrido-pyrimidine derivatives |
Feb, 2032
(8 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Mar 24, 2030 |
New Chemical Entity Exclusivity (NCE) | Mar 24, 2028 |
Drugs and Companies using LENIOLISIB PHOSPHATE ingredient
NCE-1 date: 2027-03-25
Market Authorisation Date: 24 March, 2023
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7326696 | PARATEK PHARMS INC | Amino-methyl substituted tetracycline compounds |
Sep, 2023
(3 months from now) | |
US7553828 | PARATEK PHARMS INC | 9-aminomethyl substituted minocycline compounds |
Jun, 2024
(1 year, 3 days from now) | |
US8383610 | PARATEK PHARMS INC | Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline |
Sep, 2030
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9265740 | PARATEK PHARMS INC | Minocycline compounds and methods of use thereof |
Mar, 2029
(5 years from now) | |
US10124014 | PARATEK PHARMS INC | Minocycline compounds and methods of use thereof |
Mar, 2029
(5 years from now) | |
US9724358 | PARATEK PHARMS INC | Minocycline compounds and methods of use thereof |
Mar, 2029
(5 years from now) | |
US9314475 | PARATEK PHARMS INC | Oral and injectable formulations of tetracycline compounds |
Mar, 2031
(7 years from now) | |
US10111890 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and uses thereof |
Aug, 2037
(14 years from now) | |
US10835542 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(14 years from now) | |
US10383884 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(14 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Oct 2, 2023 |
Generating Antibiotic Incentives Now (GAIN) | Oct 2, 2028 |
Drugs and Companies using OMADACYCLINE TOSYLATE ingredient
NCE-1 date: 2027-10-03
Market Authorisation Date: 02 October, 2018
Treatment: Treatment of bacterial skin and skin structure infection; Treatment of bacterial skin and skin structure infections; Treatment of subjects having bacterial skin or skin structure infection; Treatment ...
Dosage: TABLET;ORAL
54
United States
22
Japan
17
European Union
14
China
13
Australia
10
Korea, Republic of
9
Canada
9
Taiwan
7
Brazil
6
Spain
6
Denmark
6
EA
6
Croatia
6
Mexico
5
Russia
5
Portugal
5
Slovenia
4
Poland
4
Singapore
4
South Africa
4
Hungary
3
Hong Kong
3
New Zealand
3
Cyprus
3
Lithuania
2
Austria
2
Philippines
2
Czech Republic
2
Morocco
2
Argentina
2
Israel
2
Chile
2
Ecuador
2
Colombia
2
Tunisia
1
Malaysia
1
Turkey
1
Germany
1
Ukraine
1
Norway
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8399520 | STEMLINE THERAP | Selective estrogen receptor modulator |
Dec, 2023
(6 months from now) | |
US7612114 | STEMLINE THERAP | Selective estrogen receptor modulator |
Aug, 2026
(3 years from now) | |
US10385008 | STEMLINE THERAP | Polymorphic forms of RAD1901-2HCL |
Jan, 2038
(14 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10071066 | STEMLINE THERAP | Method of treating cancer using selective estrogen receptor modulators |
Oct, 2034
(11 years from now) | |
US10420734 | STEMLINE THERAP | Method of treating cancer using selective estrogen receptor modulators |
Oct, 2034
(11 years from now) | |
US10745343 | STEMLINE THERAP | Polymorphic forms of RAD1901-2HCl |
Jan, 2038
(14 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 27, 2028 |
Drugs and Companies using ELACESTRANT DIHYDROCHLORIDE ingredient
NCE-1 date: 2027-01-27
Market Authorisation Date: 27 January, 2023
Treatment: Treatment of an er-positive breast cancer following at least one line of endocrine therapy; Treatment of an er-positive breast cancer
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9670147 | REATA PHARMS | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
Apr, 2029
(5 years from now) | |
US8124799 | REATA PHARMS | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
Dec, 2029
(6 years from now) | |
US8993640 | REATA PHARMS | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
Apr, 2033
(9 years from now) | |
US9701709 | REATA PHARMS | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
Apr, 2033
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8440854 | REATA PHARMS | Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17 |
Apr, 2029
(5 years from now) | |
US11091430 | REATA PHARMS | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 |
Apr, 2029
(5 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Feb 28, 2030 |
New Chemical Entity Exclusivity (NCE) | Feb 28, 2028 |
Drugs and Companies using OMAVELOXOLONE ingredient
NCE-1 date: 2027-02-28
Market Authorisation Date: 28 February, 2023
Treatment: Treatment of friedreich's ataxia in adults and adolescents aged 16 years and older
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10961190 | TETRAPHASE PHARMS | Crystalline forms of eravacycline |
Oct, 2037
(14 years from now) | |
US11578044 | TETRAPHASE PHARMS | Crystalline forms of eravacycline |
Oct, 2037
(14 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8796245 | TETRAPHASE PHARMS | C7-fluoro substituted tetracycline compounds |
Aug, 2029
(6 years from now) | |
US8906887 | TETRAPHASE PHARMS | C7-fluoro substituted tetracycline compounds |
Dec, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Aug 27, 2023 |
Generating Antibiotic Incentives Now (GAIN) | Aug 27, 2028 |
Drugs and Companies using ERAVACYCLINE DIHYDROCHLORIDE ingredient
NCE-1 date: 2027-08-28
Market Authorisation Date: 27 August, 2018
Treatment: Treatment of complicated intra-abdominal infections in patients 18 years of age and older
Dosage: POWDER;INTRAVENOUS
15
United States
5
Japan
4
China
4
Korea, Republic of
4
European Union
3
Spain
3
Hong Kong
3
Poland
3
Argentina
3
New Zealand
3
Israel
3
Taiwan
2
Denmark
2
RS
2
Singapore
2
Croatia
2
Cyprus
2
Portugal
2
Mexico
2
Slovenia
2
Hungary
1
Philippines
1
Brazil
1
Canada
1
Morocco
1
Norway
1
San Marino
1
Australia
1
Netherlands
1
Colombia
1
Lithuania
1
Luxembourg
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7220862 | PFIZER | Calcitonin gene related peptide receptor antagonists |
Jan, 2024
(7 months from now) | |
US8481546 | PFIZER | CGRP receptor antagonist |
Oct, 2031
(8 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7314883 | PFIZER | Anti-migraine treatments |
Dec, 2023
(6 months from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 9, 2028 |
Drugs and Companies using ZAVEGEPANT HYDROCHLORIDE ingredient
NCE-1 date: 2027-03-10
Market Authorisation Date: 09 March, 2023
Treatment: Administration of zavegepant for acute treatment of migraine with or without aura
Dosage: SPRAY, METERED;NASAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9688711 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(5 years from now) | |
US8383596 | CIPLA USA | Antibacterial aminoglycoside analogs |
Jun, 2031
(8 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8822424 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(5 years from now) | |
US9266919 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(5 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jun 25, 2023 |
Generating Antibiotic Incentives Now (GAIN) | Jun 25, 2028 |
Drugs and Companies using PLAZOMICIN SULFATE ingredient
NCE-1 date: 2027-06-26
Market Authorisation Date: 25 June, 2018
Treatment: Method of using plazomicin to treat bacterial infections
Dosage: SOLUTION;INTRAVENOUS
11
United States
2
China
2
Japan
2
European Union
1
Spain
1
Denmark
1
Poland
1
Brazil
1
Canada
1
EA
1
Croatia
1
Korea, Republic of
1
Cyprus
1
Israel
1
Portugal
1
Taiwan
1
Mexico
1
Australia
1
Lithuania
1
Slovenia
1
Hungary
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic